# Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus

> **NCT00913367** · PHASE4 · COMPLETED · sponsor: **Handok Inc.** · enrollment: 110 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** glimepiride + insulin glargine (Amaryl + Lantus)
- **DRUG:** glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)

## Key facts

- **NCT ID:** NCT00913367
- **Lead sponsor:** Handok Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2013-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00913367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00913367, "Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00913367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*